In a study conducted by Jeong et al., administration of EZN-2968 at a dose of 18 mg/kg twice within a 6-week cycle resulted in disease stabilization in one patient with refractory solid tumors and a reduction in HIF-1α protein levels in tumor biopsies from two patients [224]. The gene discussed is HIF1A; the disease is neoplasm.